{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"Chapter 2: Bile Acid Sequestrants: Rediscovering an Alternative to Statins - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"fvTF7Rb07t\"><a href=\"https:\/\/themedicalxchange.com\/en\/review\/strategies-beyond-statins-for-control-of-dyslipi-2\/\">Chapter 2: Bile Acid Sequestrants: Rediscovering an Alternative to Statins<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/review\/strategies-beyond-statins-for-control-of-dyslipi-2\/embed\/#?secret=fvTF7Rb07t\" width=\"600\" height=\"338\" title=\"&#8220;Chapter 2: Bile Acid Sequestrants: Rediscovering an Alternative to Statins&#8221; &#8212; The Medical Xchange\" data-secret=\"fvTF7Rb07t\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2013\/01\/Dyslipidemia_2504_Hegele_Fig_1.PNG","thumbnail_width":960,"thumbnail_height":720,"description":"Bile acid sequestrants have been employed in the treatment of dyslipidemias for nearly 50 years. Over the past two decades, their role has been overshadowed by HMG CoA reductase inhibitors (statins), which produce larger reductions in low density lipoprotein cholesterol (LDL-C) levels and have been more extensively studied in multinational clinical trials. However, bile acid sequestrants can offer substantial reductions in LDL-C making them an appropriate substitute in patients who cannot tolerate statins and an adjunctive therapy in patients who are not reaching treatment goals on statins alone. The lipid lowering mechanism of bile acid sequestrants, which is now understood in detail that was not available when these agents were first shown to reduce cardiovascular events, is complementary and additive to that of statins. Newer formulations of bile acid sequestrants may make this class of drug more convenient and better tolerated."}